Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sisram MedicalSRAMF 57 Debt-to-Equity is 0.11 as of Dec. 2025, which is 10% above its 10-year median of 0.10. GuruFocus rates SRAMF with a GF Score™ of 57/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Sisram Medical ranks better than 66.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sisram Medical's Debt-to-Equity or its related term are showing as below:
SRAMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.1 Max: 1.45
Current: 0.11
During the past 12 years, the highest Debt-to-Equity Ratio of Sisram Medical was 1.45. The lowest was 0.01. And the median was 0.10.
SRAMF's Debt-to-Equity is ranked better than 66.1% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SRAMF: 0.11
Sisram Medical (OTCPK:SRAMF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sisram Medical Debt-to-Equity Related Terms
Sisram Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sisram Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sisram Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sisram Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical (SRAMF) has a Debt-to-Equity of 0.11 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sisram Medical and its competitors. This is 10% above median its historical median of 0.10. Over the past decade, Sisram Medical's Debt-to-Equity has ranged from 0.01 to 1.45. According to the industry distribution chart, Sisram Medical ranks #239 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Sisram Medical's Debt-to-Equity too high?
Sisram Medical's current Debt-to-Equity of 0.11 is 10% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.45. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sisram Medical's value of 0.11 is 52.2% below this industry median. Based on the distribution chart, Sisram Medical ranks #239 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sisram Medical has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #239 out of 705 companies for Debt-to-Equity. This puts Sisram Medical in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Sisram Medical's value of 0.11 is 52.2% below this benchmark. Historically, Sisram Medical's own Debt-to-Equity has ranged from 0.01 to 1.45 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 0.23, Sisram Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current Debt-to-Equity of 0.11 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current Debt-to-Equity is 0.11, which is 10% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.44 — trading 55.3% below its estimated fair value. The current Debt-to-Equity is 0.11, which is 10% above median its 10-year median of 0.10 and 52.2% below the Medical Devices & Instruments industry median of 0.23. Sisram Medical's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Debt-to-Equity is 0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
Debt-to-Equity: 0.11 (10% above median its 10-year median of 0.10)
GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
Industry Position: 52.2% below the Medical Devices & Instruments median (#239 of 705)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
57GF Score
Get the complete analysis for SRAMF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
